NCT06243614 - Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD | Biotech Hunter

Enrollment

410

Participants

Timeline

Start Date

July 24, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions

Generalized Anxiety Disorder

Interventions

DRUG

Buagafuran capsules, 15mg/ capsule

Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;

DRUG

Buspirone tablets, 5mg/ tablet

Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.

DRUG

Buagafuran capsules mimic, 0mg/ capsule

Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;

DRUG

Buspirone tablets mimic, 0mg/ tablet

Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.

Trial Locations (1)

102600

RECRUITING

Beijing Union Pharmaceutical Factory Ltd, Beijing